Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.40 |
| ▸ | LIPC | P11150 | 3/20 | 0.40 |
| ▸ | MMP1 | P03956 | 4/20 | 0.38 |
| ▸ | MMP2 | P08253 | 4/20 | 0.38 |
| ▸ | MMP3 | P08254 | 4/20 | 0.38 |
| ▸ | MMP9 | P14780 | 4/20 | 0.38 |
| ▸ | MMP8 | P22894 | 4/20 | 0.38 |
| ▸ | MMP13 | P45452 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP7 | P09237 | 3/20 | 0.37 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14729198 | 0.93 | GPR119 (0.40) | GPR119LIPGLIPCALDH1A1CLK1 | |
| SCHEMBL14729096 | 0.92 | GPR119 (0.49) | GPR119LIPGLIPCMMP1MMP2 | |
| SCHEMBL14729197 | 0.90 | GPR119 (0.41) | GPR119LIPGLIPCALDH1A1CLK1 | |
| SCHEMBL14729195 | 0.86 | GPR119 (0.41) | GPR119ALDH1A1CLK1JAK3 | |
| SCHEMBL14729201 | 0.85 | CLK1 (0.41) | GPR119ALDH1A1CLK1JAK3 | |
| SCHEMBL14729093 | 0.85 | GPR119 (0.47) | GPR119LIPGLIPCALDH1A1CLK1 | |
| SCHEMBL14729095 | 0.84 | GPR119 (0.48) | GPR119ALDH1A1CLK1 | |
| SCHEMBL14729100 | 0.84 | IKBKB (0.44) | GPR119LIPCALDH1A1CLK1JAK3 | |
| SCHEMBL2591259 | 0.84 | GPR119 (0.43) | GPR119ALDH1A1CLK1JAK3 | |
| SCHEMBL14729097 | 0.82 | MAPT (0.45) | GPR119ALDH1A1CLK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940716-B2 | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053345-A1 | BICYCLIC HETEROARLY ANALOGUES AS GPR119 MODULATORS | GPR119, GPR139, GPR4 | GPR119 1/4885LIPG 1497/4885LIPC 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.